Nanodelivery of phytobioactive compounds for treating aging-associated disorders
- PDF / 1,751,004 Bytes
- 23 Pages / 547.087 x 737.008 pts Page_size
- 58 Downloads / 175 Views
REVIEW
Nanodelivery of phytobioactive compounds for treating aging-associated disorders Oleh Lushchak & Olha Strilbytska & Alexander Koliada & Alina Zayachkivska & Nadia Burdyliuk & Ihor Yurkevych & Kenneth B. Storey & Alexander Vaiserman
Received: 18 August 2019 / Accepted: 4 October 2019 # American Aging Association 2019
Abstract Aging population presents a major challenge for many countries in the world and has made the development of efficient means for healthspan extension a priority task for researchers and clinicians worldwide. Anti-aging properties including antioxidant, anti-inflammatory, anti-tumor, and cardioprotective activities have been reported for various phytobioactive compounds (PBCs) including resveratrol, quercetin, curcumin, catechin, etc. However, the therapeutic potential of orally administered PBCs is limited by their poor stability, bioavailability, and solubility in the gastrointestinal tract. Recently, innovative nanotechnologybased approaches have been developed to improve the bioactivity of PBCs and enhance their potential in preventing and/or treating age-associated disorders, primarily those caused by aging-related chronic inflammation. PBC-loaded nanoparticles designed for oral
O. Lushchak (*) : O. Strilbytska : A. Zayachkivska : N. Burdyliuk : I. Yurkevych Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, 57 Shevchenka str., Ivano-Frankivsk 76018, Ukraine e-mail: [email protected] A. Koliada : A. Vaiserman (*) Laboratory of Epigenetics, D.F. Chebotarev Institute of Gerontology, NAMS, 67 Vyshgorodska str., Kyiv 04114, Ukraine e-mail: [email protected] K. B. Storey Department of Biology, Carleton University, 1125 Colonel by Drive, Ottawa, Ontario K1S 5B6, Canada
administration provide many benefits over conventional formulations, including enhanced stability and solubility, prolonged half-life, improved epithelium permeability and bioavailability, enhanced tissue targeting, and minimized side effects. The present review summarizes recent advances in this rapidly developing research area. Keywords Aging . Age-associated disorder . Phytobioactive compound . Bioavailability . Nanoparticle . Antioxidant . Anti-inflammatory activity
Introduction Over the past decades, the average life expectancy has been extended in all developed countries. According to the current demographic projections, the number of people over the age of 65 will rise worldwide from 524 million in 2010 to nearly 1.5 billion in 2050 (World Health Organization 2012). However, the trends observed in the rise in longevity are not commonly accompanied by the same trends toward the human healthspan extension (Hansen and Kennedy 2016). A rapid population aging presents an important challenge for most developed countries because aging is a major risk factor for almost all chronic pathological conditions. The incidence of age-associated disorders, including cardiovascular and neurodegenerative diseases, osteoporosis, type 2 diabetes, and different types of cancers, has been r
Data Loading...
